List of Detectnet drug patents
Detectnet is owned by Radiomedix.
Detectnet contains Copper Dotatate Cu-64.
Detectnet has a total of 3 drug patents out of which 0 drug patents have expired.
Detectnet was authorised for market use on 03 September, 2020.
Detectnet is available in solution;intravenous dosage forms.
Detectnet can be used as use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients.
Drug patent challenges can be filed against Detectnet from September, 2024.
The generics of Detectnet are possible to be released after 23 August, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10159759 | RADIOMEDIX | Pet tracer for imaging of neuroendocrine tumors |
Aug, 2032
(9 years from now) | |
| US10383961 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(9 years from now) | |
| US11160888 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 3, 2025 |
| Orphan Drug Exclusivity (ODE) | Sep 3, 2027 |
Drugs and Companies using COPPER DOTATATE CU-64 ingredient
NCE-1 date: September, 2024
Market Authorisation Date: 03 September, 2020
Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients
Dosage: SOLUTION;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic